"Hemophilia B is the first clinical application of our IVPRP which can be applied to many other diseases that are currently treated by protein replacement including hemophilia A and lysosomal storage disorders," said
IMPRESSIVE WORK !!
Thursday, September 10, 2015
First Application of Sangamo's In Vivo Protein Replacement Platform (IVPRP) for Potential Cure of Hemophilia B
From today's press release:
"Hemophilia B is the first clinical application of our IVPRP which can be applied to many other diseases that are currently treated by protein replacement including hemophilia A and lysosomal storage disorders," saidGeoff Nichol , M.B., Ch.B., Sangamo's executive vice president of research and development. "Successful review, by the NIH RAC, of the first human in vivo genome editing clinical protocol is a major milestone for Sangamo. We appreciate this careful consideration and unanimous approval of our proposed clinical trial and look forward to the commencement of our Phase 1 study in the near future."
IMPRESSIVE WORK !!
"Hemophilia B is the first clinical application of our IVPRP which can be applied to many other diseases that are currently treated by protein replacement including hemophilia A and lysosomal storage disorders," said
IMPRESSIVE WORK !!
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment